Previous 10 | Next 10 |
2023-09-12 17:31:30 ET Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs analyst. Geron shares could shoot up to $4.0 Jenkins upgraded the biotech stock to “buy” on...
2023-09-12 13:55:56 ET Summary GERN's New Drug Application for imetelstat in lower-risk myelodysplastic syndromes has been accepted for standard review by the FDA. The FDA's approval of Bristol-Myers Squibb's Reblozyl as a first-line treatment in lower-risk MDS may impact the posi...
2023-09-12 09:38:17 ET More on Geron Seeking Alpha’s Quant Rating on Geron Historical earnings data for Geron Financial information for Geron FDA's Twist In Geron's Telomerase Tale (Rating Downgrade) Geron Corporation ( GERN ) Q2 2023 Ear...
2023-09-11 16:42:57 ET More on Geron Seeking Alpha’s Quant Rating on Geron Historical earnings data for Geron Financial information for Geron FDA's Twist In Geron's Telomerase Tale (Rating Downgrade) Geron Stock: These Prices Are Unlikely To Re...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Ol...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global Healthcare Conference in New York ...
2023-09-01 14:21:59 ET Wedbush has added Geron ( NASDAQ: GERN ) to its Best Ideas List, a recent sell-off in shares and its “high acquisition potential.” The investment bank said it believes Geron shares have been “unfairly sold off” in the wake of an...
2023-08-29 10:00:37 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-23 13:00:00 ET Summary Geron aims for FDA approval of imetelstat in June 2024 for hematologic malignancies, targeting an H1 2024 launch. Recent FDA decision for standard review of imetelstat suggests caution and potential regulatory challenges. Geron's financial health...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...